1025637-00-6

Basic information

• Product Name: 2-((4-DIMETHYLAMINOPHENYL)METHYLENE)-5,6-DIMETHOXYINDAN-1-ONE
• Synonyms: 2-((4-DIMETHYLAMINOPHENYL)METHYLENE)-5,6-DIMETHOXYINDAN-1-ONE;(2Z)-2-{[4-(dimethylamino)phenyl]methylidene}-5,6-dimethoxy-2,3-dihydro-1H-inden-1-one
• CAS NO: 1025637-00-6
• Molecular Formula: C₂₀H₂₁NO₃
• Molecular Weight: 323.39
• Mol File: 1025637-00-6.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-((4-DIMETHYLAMINOPHENYL)METHYLENE)-5,6-DIMETHOXYINDAN-1-ONE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-((4-DIMETHYLAMINOPHENYL)METHYLENE)-5,6-DIMETHOXYINDAN-1-ONE(1025637-00-6)
• EPA Substance Registry System: 2-((4-DIMETHYLAMINOPHENYL)METHYLENE)-5,6-DIMETHOXYINDAN-1-ONE(1025637-00-6)

Safety Data

• Hazardous Substances Data: 1025637-00-6(Hazardous Substances Data)

Upstream product

• 459-57-4 4-fluorobenzaldehyde 
• 2107-69-9 5,6-dimethoxy-1-indanone 
• 100-10-7 4-dimethylamino-benzaldehyde 

Relevant articles and documents

Multifunctional indanone–chalcone hybrid compounds with anti-β-amyloid (Aβ) aggregation, monoamine oxidase B (MAO-B) inhibition and neuroprotective properties against Alzheimer’s disease

To discover multifunctional agents for the treatment of Alzheimer’s disease (AD), a series of indanone–chalcone hybrid compounds were designed and synthesized based on the multitarget-directed ligand strategy. Their monoamino oxidases (MAO-A and MAO-B) an

Multitarget-directed benzylideneindanone derivatives: Anti-β-amyloid (Aβ) aggregation, antioxidant, metal chelation, and monoamine oxidase B (MAO-B) inhibition properties against Alzheimer's disease

A novel series of benzylideneindanone derivatives were designed, synthesized, and evaluated as multitarget-directed ligands against Alzheimer's disease. The in vitro studies showed that most of the molecules exhibited a significant ability to inhibit self-induced β-amyloid (Aβ 1-42) aggregation (10.5-80.1%, 20 μM) and MAO-B activity (IC 50 of 7.5-40.5 μM), to act as potential antioxidants (ORAC-FL value of 2.75-9.37), and to function as metal chelators. In particular, compound 41 had the greatest ability to inhibit Aβ1-42 aggregation (80.1%), and MAO-B (IC50 = 7.5 μM) was also an excellent antioxidant and metal chelator. Moreover, it is capable of inhibiting Cu(II)-induced Aβ1-42 aggregation and disassembling the well-structured Aβ fibrils. These results indicated that compound 41 is an excellent multifunctional agent for the treatment of AD.